發(fā)布時(shí)間：2018-04-20 18:42

  本文選題：腸易激綜合征 + 有益菌種��； 參考：《新疆醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的：探討益生菌治療腸易激綜合征(IBS)的臨床療效及安全性。方法：計(jì)算機(jī)檢索PubMed.國(guó)際Cochrane中心、Embase.中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)、相關(guān)期刊論文、萬(wàn)方數(shù)據(jù)庫(kù)、維普數(shù)據(jù)庫(kù),收集益生菌治療IBS的隨機(jī)對(duì)照試驗(yàn)(RCT),并手工檢索已獲文獻(xiàn)的參考文獻(xiàn),由兩位評(píng)價(jià)者按照納入和排除標(biāo)準(zhǔn)篩選、提取資料并行方法學(xué)質(zhì)量評(píng)價(jià),采用RevMan5.0軟件對(duì)數(shù)據(jù)行Meta分析。結(jié)果：共納入19個(gè)RCT,2172例患者,Meta分析結(jié)果顯示：益生菌較安慰劑在改善患者總體癥狀積分[SMD=-0.18,95%CI(-0.28,-0.08),P=0.0006]、腹痛[SMD=-0.13,95%CI(-0.21,-0.04),P=0.003]、腹脹[SMD=-0.15,95%CI(-0.25,-0.05), P=0.004]、排便不適感[SMD=-0.15,95%CI(0.27,-0.02),P=0.02]方面均有顯著意義,在總體生活質(zhì)量[SMD=0.09,95%CI(-0.08,0.25),P=0.30]、不良反應(yīng)發(fā)生率[RR=0.91,95%CI(0.71,1.16),P=0.45]方面無顯著意義。結(jié)論：目前證據(jù)顯示益生菌制劑能有效改善IBS患者的臨床癥狀,且安全性好,但現(xiàn)有RCT在力法質(zhì)量學(xué)以及研究設(shè)計(jì)上存在一定不足,今后的研究應(yīng)在菌株、劑量、療程、IBS亞組患者方面進(jìn)行嚴(yán)謹(jǐn)、高質(zhì)量、大樣本長(zhǎng)期隨訪的臨床研究予以證實(shí)。
[Abstract]:Objective: to investigate the clinical efficacy and safety of probiotics in the treatment of irritable bowel syndrome (IBS). Methods: PubMed. was searched by computer. International Cochrane Center. Chinese Biomedical Literature Database, full text Database of Chinese Journals, Wanfang Database, Wipu Database, Random controlled trial of probiotic treatment of IBS, and manual retrieval of references obtained, According to the inclusion and exclusion criteria, two evaluators were selected to extract the data and evaluate the quality of parallel methodology. The RevMan5.0 software was used to analyze the data row Meta. There was no significant difference in the overall quality of life (SMD-0.09 / 95) and the incidence of adverse reactions (RRR0.91 / 95CI0.71 / 1.16 / P0.45), and there was no significant difference in the overall quality of life (SMD-0.08) and 0.25% (P = 0.30), and there was no significant difference in the incidence of adverse reactions. Conclusion: the current evidence shows that probiotics can effectively improve the clinical symptoms of patients with IBS, and the safety is good, but there are some deficiencies in the quality of force method and the research and design of the existing RCT, the future research should be in the strain, dosage. A rigorous, high-quality, long-term follow-up study was conducted in the IBS subgroup.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R574.4

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 張芳芹;徐桂芳;鄒曉平;;益生菌和腸易激綜合征[J];國(guó)際消化病雜志;2012年01期

2 張蕾;顧芳;白鵬;呂愈敏;;16S rDNA熒光定量PCR法對(duì)腸易激綜合征患者腸道目標(biāo)菌群的分析[J];山東醫(yī)藥;2009年28期

3 潘國(guó)宗,魯素彩,柯美云,韓少梅,郭慧平,方秀才;北京地區(qū)腸易激綜合征的流行病學(xué)研究:一個(gè)整群、分層、隨機(jī)的調(diào)查[J];中華流行病學(xué)雜志;2000年01期

4 Philippe Ducrotté;Prabha Sawant;Venkataraman Jayanthi;;Clinical trial:Lactobacillus plantarum 299v(DSM 9843)improves symptoms of irritable bowel syndrome[J];World Journal of Gastroenterology;2012年30期

，

本文編號(hào)：1778971